EMA
Beyond's analysis on EMA
- — AbbVie seeks EMA approval for subcutaneous risankizumab induction in Crohn’s disease, expanding its immunology portfolio
- — EMA PRIME designation accelerates AbelZeta's lupus therapy C-CAR168 toward faster regulatory approval and market entry
Recent news mentioning EMA
- — Snap Has Launched Its High-Powered Glasses. Will There Be Enough Demand?
- — Führung: „Die Anerkennung für meine Arbeit bekommt jemand über mir“ – Das Leid der stillen Schaffer
- — ZEELOOL y Aimee Song lanzan una nueva colección de gafas con el lema "Let's Frame Your Vibe"
- — 'We remain committed to China, continue to invest for the long term': Amway CEO
- — Nemak, S.A.B. de C.V. Announces Results of Tender Offer and Consent Solicitation for Any and All of Its Outstanding 2.250% Senior Notes Due 2028
- — Grand Seiko mejora el diseño de su reloj más demandado
- — Global Payments Growth Set to Slow to 5% as Investors Demand Proof of Durable Value
- — Snorkel AI triples valuation to $3.5B as demand for AI training data booms
- — La "necesaria dosis de cuestionamiento" del presidente saliente del Liceo, Salvador Alemany
- — Trump, la IA y las catástrofes marcan la Semana del Clima
- — Global Energy Demand Set to Jump 60% by 2060 as Developing Nations Power Up
- — HII Expands Unmanned Production Facility by 25% to Meet Growing Global Maritime Demand